Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases

Clinical Cancer Research

Volumn 15, Issue 6, 2009, Pages 2174-2180

  Chavin, Grant ^a   Sheinin, Yuri ^a   Crispen, Paul L ^a   Boorjian, Stephen A ^a   Roth, Timothy J ^a   Rangel, Laureano ^a   Blute, Michael L ^a   Sebo, Thomas J ^a   Tindall, Don J ^a   Kwon, Eugene D ^a,b   Karnes, R Jeffrey ^a  

^a Department of Urology ^*  (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIGAND; PROTEIN B7 H3; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER CELL; CANCER GROWTH; CANCER MORTALITY; DISEASE COURSE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION;

ADULT; AGED; ANDROGEN ANTAGONISTS; ANTIGENS, CD; BONE NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RECEPTORS, IMMUNOLOGIC; T-LYMPHOCYTES;

EID: 63549150834     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2262     Document Type: Article

References (38)

1. Khan MA, Han M, Partin AW, Epstein JI,Walsh PC. Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003. Urology 2003;62:86-91.
2. Roehl KA, Han M, Ramos CG, AntenorJA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 2004;172:910-4.
3. Shipley WU, Thames HD, Sandler HM, et al. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA 1999;281: 1598-604.
4. Penson DF, Chan JM. Prostate cancer. J Urol 2007; 177:2020-9.
5. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
6. Petrylak DP,Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20.
7. Ribas A. Genetically modified dendritic cells for cancer immunotherapy. Curr Gene Ther 2005;5:619-28.
8. Thomas-Kaskel AK,Waller CF, Schultze-Seemann W, Veelken H. Immunotherapy with dendritic cells for prostate cancer. IntJ Cancer 2007;121:467-73.
9. Sonpavde G, Spencer DM, Slawin KM. Vaccine therapy for prostate cancer. Urol Oncol 2007;25:451 -9.
10. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005;23:515-48.
11. Flies DB, Chen L. The new B7s: playing a pivotal role in tumor immunity. J Immunother 2007;30:251-60.
12. Carreno BM, Collins M.TheB7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol 2002;20:29-53.
13. Inman BA, Frigola X, Dong H, Kwon ED. Costimulation, coinhibition and cancer. Curr Cancer DrugTargets 2007;7:15-30.
14. Dong H, Strome SE, Salomao DR, et al. Tumor- associated B7-1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793-800.
15. Zang X, LokeP, KimJ, MurphyK,Waitz R, AllisonJP. B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci U S A 2003; 100:10388-92.
16. Thompson RH, KuntzSM, Leibovich BC, et al.Tumor B7-1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006;66:3381-5.
17. Krambeck AE, Thompson RH, Dong H, et al. B7-4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival.ProcNatlAcadSciUSA2006;103: 10391-6.
18. Inman BA, Sebo TJ, Frigola X, et al. PD-L1 (B7-1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer 2007;109:1499-505.
19. Roth TJ, Sheinin Y, Lohse CM, et al. B7-3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res 2007;67:7893-900.
20. Zang X,Thompson RH, Al-Ahmadie HA, et al. B7-3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A 2007;104: 19458-63.
21. Sebo TJ, Cheville JC, Riehle DL, et al. Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen: a report of 454 cases. Cancer 2001;91:2196-204.
22. Blute ML, Bergstralh EJ, Iocca A, Scherer B, Zincke H. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol 2001;165:119-25.
23. Shah NT,Tuttle SE, Strobel SL, Gandhi L. Prostatic carcinoma metastatic to bone: sensitivity and specificity of prostate-specific antigen and prostatic acid phosphatase in decalcified material. J Surg Oncol 1985;29:265-8.
24. Athanasou NA, Quinn J, Heryet A, Woods CG, McGee JO. Effect of decalcification agents on immunoreactivity of cellular antigens. JClin Pathol 1987;40:874-8.
25. Steffens J, Friedmann W, Lobeck H. Immunohisto- chemical diagnosis of the metastasizing prostatic carcinoma. Eur Urol 1985;11:91-4.
26. Mukai K,Yoshimura S, Anzai M. Effects of decalcification on immunoperoxidase staining. Am J Surg Pathol 1986;10:413-9.
27. Cheville JC,Tindall D, Boelter C, et al. Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival. Cancer 2002;95:1028-36.
28. Prasad DV, Nguyen T, Li Z, et al. Murine B7-3 is a negative regulator of T cells. J Immunol 2004;173:2500-6.
29. Castriconi R, DonderoA, Augugliaro R, et al. Identification of 4Ig-B7-3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis. Proc Natl Acad Sci U S A 2004;101: 12640-5.
30. SuhWK, Gajewska BU, Okada H,etal.TheB7 family member B7-3 preferentially down-regulatesT helper type 1-mediated immune responses. Nat Immunol 2003;4:899-906.
31. Suh WK, Wang SX, Jheon AH, et al. The immune regulatory protein B7-3 promotes osteoblast differentiation and bone mineralization. Proc Natl Acad Sci USA 2004;101:12969-73.
32. Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 2004;91:528-39.
33. Hubert RS,Vivanco I, Chen E, et al. STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc Natl Acad Sci U S A 1999;96:14523-8.
34. Zhang S,Zhang HS,ReuterVE, Slovin SF,Scher HI, Livingston PO. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin Cancer Res1998;4:295-302.
35. Elgamal AA, Holmes EH, Su SL, et al. Prostate- specific membrane antigen (PSMA): current benefits and future value. Semin Surg Oncol 2000;18:10-6.
36. Ghosh A, Wang X, Klein E, Heston WD. Novel role of prostate-specific membrane antigen in suppressing prostate cancer invasiveness. Cancer Res 2005;65:727-31.
37. Bullock MJ, Srigley JR, Klotz LH, Goldenberg SL. Pathologic effect of neoadjuvant cyproterone acetate on nonneoplastic prostate, prostatic intra- epithelial neoplasia, and adenocarcinoma: a detailed analysis of radical prostatectomy specimens from a randomized trial. Am J Surg Pathol 2002;26:1400-13.
38. Bently G, Dey J, SakrWA, Wood DP, Pontes JE, Grignon, DJ. Significance of the Gleason scoring system after neoadjuvant hormonal therapy. Mol Urol 2000;4:125-31.